Health care covers pharmaceutical and biotech companies, makers of medical devices and equipment, health insurers and hospital operators. Demand for health care does not fall much in recessions, so the sector is often treated as defensive. Individual drug companies can still move sharply on trial results and regulatory decisions.
| Company | Last | Change | % change | Market value | P/E |
|---|---|---|---|---|---|
| Eli LillyLLY | 1,183.46 | +1.57 | +0.13% | ||
| UnitedHealth GroupUNH | 376.59 | +1.58 | +0.42% | ||
| Johnson & JohnsonJNJ | 271.22 | +0.54 | +0.20% | ||
| AbbVieABBV | 264.34 | -0.78 | -0.29% | ||
| MerckMRK | 148.78 | +0.80 | +0.54% | ||
| Thermo Fisher ScientificTMO | 675.00 | -3.39 | -0.50% | ||
| Abbott LaboratoriesABT | 101.29 | +0.22 | +0.22% | ||
| Intuitive SurgicalISRG | 405.18 | +5.66 | +1.42% | ||
| AmgenAMGN | 414.61 | +8.57 | +2.11% | ||
| DanaherDHR | 224.49 | +0.72 | +0.32% | ||
| PfizerPFE | 28.67 | +0.26 | +0.92% | ||
| Boston ScientificBSX | 43.92 | -0.76 | -1.70% | ||
| Gilead SciencesGILD | 150.93 | +1.24 | +0.83% | ||
| CVS HealthCVS | 89.13 | +4.08 | +4.80% |
A hand-picked list of the largest companies in the sector, sorted by market value, not the fund's full holdings. Closing price for Sep 25, 2026 from Polygon.io. Market values from Nasdaq. P/E uses diluted earnings per share for each company's last full fiscal year, from SEC filings.